NLM Digital Collections

Search

Start Over Subjects Cost-Benefit Analysis ✖Remove constraint Subjects: Cost-Benefit Analysis

3. Cost-effective screening and treatment of Hepatitis C

Author(s):
Weiner, Janet, author
Linas, Benjamin, author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, September 2018
Subject(s):
Cost-Benefit Analysis
Hepatitis C -- diagnosis
Mass Screening -- economics
Eligibility Determination
Health Policy
Hepatitis C -- drug therapy
Insurance Coverage -- economics
Mass Screening -- trends
Medicaid -- economics
Sofosbuvir -- economics
Sofosbuvir -- therapeutic use
Practice Guidelines as Topic
Humans
United States
Centers for Disease Control and Prevention (U.S.)

4. Pharmacogenomics: a primer for policymakers

Publication:
Washington, D.C. : George Washington University, [2008]
Subject(s):
Genetic Testing
Insurance Coverage
Pharmacogenetics -- economics
Pharmacogenetics -- trends
Information Management
Cost-Benefit Analysis
Drug Industry
Health Policy
Health Services Accessibility
Health Services Research
Insurance, Pharmaceutical Services
Pharmaceutical Preparations
Pharmacogenetics -- ethics
Safety
Humans
United States

5. Increasing the value of health care: the role of nurses

Author(s):
Lindrooth, Richard C., author
Yakusheva, Olga, author
Fairman, Julie, author
Weiner, Janet, author
Naylor, Mary D., author
Pauly, Mark V., author
Publication:
[Philadelphia, Penna.] : Leonard Davis Institute of Health Economics, October 2015
Subject(s):
Cost-Benefit Analysis
Economics, Nursing
Health Care Costs
Nursing Staff, Hospital -- economics
Outcome Assessment (Health Care)
Quality of Health Care -- economics
Education, Nursing, Baccalaureate -- economics
Medicare -- economics
Nurses
Nurse's Role
Nursing Staff, Hospital -- education
Personnel Staffing and Scheduling
Reimbursement Mechanisms -- economics
Humans
United States
United States.

6. How nursing affects Medicare's outcome-based hospital payments

Author(s):
Yakusheva, Olga, author
Lindrooth, Richard C., author
Weiner, Janet, author
Spetz, Joanne, author
Pauly, Mark V., author
Publication:
[Philadelphia, Pennsylvania] : Leonard Davis Institute of Health Economics, November 2015
Subject(s):
Cost-Benefit Analysis
Medicare -- economics
Nurses
Nurse's Role
Nursing Staff, Hospital -- economics
Outcome Assessment (Health Care)
Cross Infection -- economics
Health Care Costs
Health Care Reform -- legislation & jurisprudence
Patient Readmission -- economics
Patient Readmission -- legislation & jurisprudence
Quality Indicators, Health Care
Quality of Health Care
Reimbursement, Incentive
Value-Based Purchasing
Humans
United States
United States.

7. Targeted immune modulators for rheumatoid arthritis: effectiveness and value : evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 7, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Arthritis, Rheumatoid -- immunology
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Drug Therapy, Combination
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Janus Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Tumor Necrosis Factors -- antagonists & inhibitors
Humans
United States

8. Dupilumab and crisaborole for atopic dermatitis: effectiveness and value : final evidence report and meeting summary

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 8, 2017
Subject(s):
Antibodies, Monoclonal -- therapeutic use
Dermatitis, Atopic -- drug therapy
Interleukin-4 Receptor alpha Subunit -- antagonists & inhibitors
Phosphodiesterase 4 Inhibitors -- therapeutic use
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Cyclosporine -- therapeutic use
Phosphodiesterase 4 Inhibitors -- adverse effects
Phototherapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

9. Abuse-deterrent formulations of opioids: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 8, 2017
Subject(s):
Abuse-Deterrent Formulations -- economics
Abuse-Deterrent Formulations -- statistics & numerical data
Analgesics, Opioid -- economics
Analgesics, Opioid -- therapeutic use
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- prevention & control
Prescription Drug Diversion -- statistics & numerical data
Comparative Effectiveness Research
Cost-Benefit Analysis
Delayed-Action Preparations -- economics
Delayed-Action Preparations -- therapeutic use
Drug Compounding -- economics
Drug Overdose -- mortality
Insurance Coverage -- economics
Insurance, Pharmaceutical Services -- economics
Opioid-Related Disorders -- epidemiology
Humans
United States

10. How much do older workers value employee health insurance?

Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, [2008]
Subject(s):
Consumer Behavior
Health Benefit Plans, Employee -- statistics & numerical data
Insurance Coverage -- statistics & numerical data
Aged
Cost-Benefit Analysis
Employer Health Costs -- statistics & numerical data
Health Benefit Plans, Employee -- economics
Income
Humans
United States

11. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, April 15, 2014
Subject(s):
Comparative Effectiveness Research
Hepatitis C, Chronic -- drug therapy
Heterocyclic Compounds, 3-Ring -- therapeutic use
Sulfonamides -- therapeutic use
Uridine Monophosphate -- analogs & derivatives
Uridine Monophosphate -- therapeutic use
Antiviral Agents -- economics
Antiviral Agents -- therapeutic use
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination
Genotype
Hepatitis C -- economics
Hepatitis C -- genetics
Heterocyclic Compounds, 3-Ring -- adverse effects
Heterocyclic Compounds, 3-Ring -- economics
Insurance Coverage
Interferon-alpha -- therapeutic use
Oligopeptides -- therapeutic use
Polyethylene Glycols -- therapeutic use
Proline -- analogs & derivatives
Proline -- therapeutic use
Protease Inhibitors -- economics
Protease Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Ribavirin -- therapeutic use
Sulfonamides -- adverse effects
Technology Assessment, Biomedical
Treatment Outcome
Uridine Monophosphate -- adverse effects
Uridine Monophosphate -- economics
Value-Based Purchasing
Humans
United States

12. Management of patients with opioid dependence: a review of clinical, delivery system, and policy options

Publication:
[Boston, MA] : Institute for Clinical and Economic Review, July 2014
Subject(s):
Analgesics, Opioid -- therapeutic use
Buprenorphine -- therapeutic use
Comparative Effectiveness Research
Delivery of Health Care
Health Policy
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Opiate Substitution Treatment -- economics
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- rehabilitation
Analgesics, Opioid -- administration & dosage
Analgesics, Opioid -- adverse effects
Budgets
Cohort Studies
Cost-Benefit Analysis
Counseling
Criminal Law
Drug Combinations
Drug Costs
Health Services Accessibility
Insurance Coverage
Medicaid
Medicare
Patient Care Team
Patient-Centered Care
Practice Guidelines as Topic
Treatment Outcome
Humans
New England
United States

13. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Cunningham, Courtney, author
Pearson, Steven D., author
Kazi, Dhruv S., author
Coxson, Pamela G., author
Moran, Andrew E., author
Penko, Joanne, author
Guzman, David, author
Bibbins-Domingo, Kirsten, author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, November 24, 2015
Subject(s):
Anticholesteremic Agents -- therapeutic use
Azetidines -- therapeutic use
Enzyme Inhibitors -- therapeutic use
Hypercholesterolemia -- therapy
Hyperlipoproteinemia Type II -- prevention & control
Proprotein Convertases -- economics
Serine Endopeptidases -- economics
Cholesterol, LDL
Cost-Benefit Analysis
Decision Support Techniques
Drug Costs
Drug Resistance
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Technology Assessment, Biomedical
Treatment Outcome
Value-Based Purchasing
Humans
New England
United States

14. CardioMEMS (tm) HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto (tm), Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Ollendorf, Daniel A., author
Ollendorf, Daniel A., author
Tarlochan Sandhu, Alexander, author
Chapman, Rick, author
Heidenreich, Paul A., author
Russo, Elizabeth, author
Shore, Karen K., author
Synnott, Patricia, author
Travers, Karin, author
Weissberg, Jed, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, December 1, 2015
Subject(s):
Angiotensin II Type 1 Receptor Blockers -- administration & dosage
Antihypertensive Agents -- administration & dosage
Blood Pressure Monitoring, Ambulatory -- instrumentation
Blood Pressure Monitoring, Ambulatory -- methods
Heart Failure -- diagnosis
Heart Failure -- drug therapy
Neprilysin -- administration & dosage
Tetrazoles -- administration & dosage
Valsartan -- administration & dosage
Angiotensin II Type 1 Receptor Blockers -- economics
Antihypertensive Agents -- economics
Cost-Benefit Analysis
Drug Combinations
Drug Costs
Neprilysin -- antagonists & inhibitors
Neprilysin -- economics
Outcome and Process Assessment (Health Care)
Tetrazoles -- economics
Valsartan -- economics
Humans
United States

16. Improving quality and efficiency in health care through comparative effectiveness analyses: an international perspective

Author(s):
Fairbrother, Gerry, author
O'Brien, Ellen, author
Pradhananga, Rosina, author
Chalkidou, Kalipso, author
Publication:
[Washington, D.C.] : AcademyHealth, November 2014
Subject(s):
Comparative Effectiveness Research -- methods
Delivery of Health Care
Efficiency
Internationality
Quality Improvement
Cost-Benefit Analysis
Health Care Costs -- trends
Patient Outcome Assessment
Patient-Centered Care
Technology Assessment, Biomedical -- methods
Universal Coverage
Humans
Australia
Canada
Europe
United States

17. Palliative care in the outpatient setting: a comparative effectiveness report : final report

Author(s):
Cunningham, Courtney, author
Trevers, Karin, author
Chapman, Rick, author
Loos, Anne, author
Lawler, Erin, author
Liu, Shanshan, author
Pearson, Steven D., author
Ollendorf, Daniel A., author
Publication:
Boston, MA : Institute for Clinical and Economic Review, April 27, 2016
Subject(s):
Ambulatory Care -- organization & administration
Comparative Effectiveness Research
Palliative Care -- organization & administration
Anxiety -- therapy
Caregivers
Clinical Trials as Topic
Cost Savings
Cost-Benefit Analysis
Depression -- therapy
Health Policy
Health Resources -- utilization
Health Services Accessibility
Healthcare Disparities
Insurance, Health, Reimbursement
Medicaid -- economics
Medicare -- economics
Outcome Assessment (Health Care)
Palliative Care -- manpower
Patient Education as Topic
Patient Satisfaction
Quality of Life
Research
Spirituality
Humans
United States

18. Obeticholic acid for the treatment of primary biliary cholangitis: comparative clinical effectiveness, value, and value-based price benchmarks : evidence report

Author(s):
Pearson, Steven D., author
Banken, Reiner, author
Chapman, Rick, author
Emond, Sarah K., author
Loos, Anne M., author
Russo, Elizabeth T., author
Segel, Celia S., author
Ollendorf, Daniel A., author
Chhatwal, Jagpreet, author
Hur, Chin, author
Klebanoff, Matthew, author
Samur, Sumeyye, author
Publication:
Boston, MA : Institute for Clinical and Economic Review, March 2016
Subject(s):
Bile Acids and Salts -- agonists
Cholangitis -- drug therapy
Comparative Effectiveness Research
Value-Based Purchasing
Benchmarking
Bile Acids and Salts -- adverse effects
Bile Acids and Salts -- economics
Cost-Benefit Analysis
Liver Cirrhosis -- prevention & control
Liver Transplantation
Pruritus
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

19. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 6, 2017
Subject(s):
Comparative Effectiveness Research
Multiple Sclerosis, Chronic Progressive -- drug therapy
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- economics
Antirheumatic Agents -- therapeutic use
Benchmarking
Cost-Benefit Analysis
Immunosuppressive Agents -- adverse effects
Immunosuppressive Agents -- economics
Immunosuppressive Agents -- therapeutic use
Insurance Coverage
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

20. Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 10, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Immunotherapy
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Protein Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Value-Based Purchasing
Humans
United States

21. Mepolizumab (Nucala??, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Campbell, Jonathan D., author
Chapman, Rick, author
Shore, Karen K., author
Weissberg, Jed, author
Whittington, Melanie, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016
Subject(s):
Adrenergic beta-2 Receptor Agonists -- economics
Adrenergic beta-2 Receptor Agonists -- therapeutic use
Anti-Asthmatic Agents -- administration & dosage
Anti-Asthmatic Agents -- economics
Antibodies, Monoclonal, Humanized -- administration & dosage
Antibodies, Monoclonal, Humanized -- economics
Asthma -- drug therapy
Asthma -- immunology
Eosinophilia -- drug therapy
Interleukin-5 -- immunology
Cost-Benefit Analysis
Glucocorticoids -- administration & dosage
Humans
United States

22. Insulin degludec (Tresiba??, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Chapman, Rick, author
Shore, Karen K., author
Weissberg, Jed, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, March 14, 2016
Subject(s):
Blood Glucose -- drug effects
Diabetes Mellitus, Type 1 -- drug therapy
Diabetes Mellitus, Type 2 -- drug therapy
Hypoglycemia -- prevention & control
Hypoglycemic Agents -- therapeutic use
Insulin, Long-Acting -- administration & dosage
Insulin, Long-Acting -- therapeutic use
Blood Glucose -- metabolism
Cost-Benefit Analysis
Diabetes Mellitus, Type 1 -- blood
Diabetes Mellitus, Type 1 -- complications
Diabetes Mellitus, Type 2 -- blood
Diabetes Mellitus, Type 2 -- complications
Hypoglycemia -- blood
Hypoglycemia -- chemically induced
Hypoglycemic Agents -- administration & dosage
Insulin -- adverse effects
Severity of Illness Index
Humans
United States

23. Controversies in migraine management: a technology assessment : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Weissberg, Jed, author
Shore, Karen K., author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, August 19, 2014
Subject(s):
Analgesics, Opioid -- therapeutic use
Botulinum Toxins, Type A -- therapeutic use
Emergency Medical Services
Magnetic Field Therapy
Migraine Disorders -- drug therapy
Migraine Disorders -- economics
Migraine Disorders -- prevention & control
Migraine Disorders -- therapy
Transcutaneous Electric Nerve Stimulation
Analgesics, Opioid -- adverse effects
Analgesics, Opioid -- economics
Chronic Disease
Cost-Benefit Analysis
Disease Management
Insurance Coverage
Migraine Disorders -- epidemiology
Migraine with Aura -- therapy
Randomized Controlled Trials as Topic
Technology Assessment, Biomedical
Treatment Outcome
Humans
California
United States

27. Controversies in obesity management: a technology assessment : final report

Author(s):
Ollendorf, Daniel A., author
Shore, Karen K., author
Cameron, Chris, author
Weissberg, Jed, author
Loos, Anne M., author
Synnott, Patricia, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, August 10, 2015
Subject(s):
Disease Management
Obesity -- therapy
Anti-Obesity Agents
Bariatric Surgery -- economics
Bariatric Surgery -- statistics & numerical data
Body Mass Index
Comparative Effectiveness Research
Cost-Benefit Analysis
Insurance Coverage
Obesity -- complications
Obesity -- etiology
Obesity -- prevention & control
Practice Guidelines as Topic
Technology Assessment, Biomedical
Weight Loss
Humans
United States

32. Value-based coverage policy in the United States and the United Kingdom: different paths to a common goal

Publication:
Washington, D.C. : George Washington University, [2006]
Subject(s):
Cost-Benefit Analysis
Evidence-Based Medicine
Insurance Coverage -- economics
Technology Assessment, Biomedical
Formularies as Topic
Medicaid -- economics
Medicare -- economics
Private Sector
State Government
Humans
United Kingdom
United States
United States. Agency for Healthcare Research and Quality.
Blue Cross Association.
Blue Shield Association.
Centers for Medicare & Medicaid Services (U.S.)
National Institute for Health and Clinical Excellence (Great Britain)

33. Show me the money: economic evaluations of opioid use disorder interventions

Author(s):
Murphy, Sean M., author
Polsky, Daniel, author
Meisel, Zachary, author
Mitchell, Julia, author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, May 2016
Subject(s):
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- economics
Buprenorphine -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Reward
Humans
United States

36. Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, March 23, 2018
Subject(s):
Immunotherapy, Adoptive
Leukemia, B-Cell -- drug therapy
Lymphoma, B-Cell -- drug therapy
Lymphoma, Non-Hodgkin -- drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Adult
Child
Clinical Trials as Topic
Clofarabine -- therapeutic use
Cost-Benefit Analysis
Immunotherapy, Adoptive -- adverse effects
Immunotherapy, Adoptive -- economics
Receptors, Chimeric Antigen -- therapeutic use
Treatment Outcome
Humans
United States

37. Emicizumab for hemophilia A with inhibitors: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2018
Subject(s):
Antibodies, Bispecific -- therapeutic use
Antibodies, Monoclonal -- therapeutic use
Hemophilia A -- drug therapy
Antibodies, Bispecific -- adverse effects
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Treatment Outcome
Humans
United States

38. Modulator treatments for cystic fibrosis: effectiveness and value : final evidence report and meeting summary

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 7, 2018
Subject(s):
Cystic Fibrosis -- drug therapy
Cystic Fibrosis Transmembrane Conductance Regulator -- therapeutic use
Clinical Trials as Topic
Cost of Illness
Cost-Benefit Analysis
Cystic Fibrosis Transmembrane Conductance Regulator -- adverse effects
Treatment Outcome
Humans
United States

39. Elagolix for treating endometriosis: final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):
Endometriosis -- drug therapy
Gonadotropin-Releasing Hormone -- antagonists & inhibitors
Analgesics -- adverse effects
Analgesics -- therapeutic use
Cost-Benefit Analysis
Pain -- drug therapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

40. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : condition update : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):
Immunologic Factors -- therapeutic use
Immunomodulation
Psoriasis -- drug therapy
Certolizumab Pegol -- therapeutic use
Clinical Trials as Topic
Cost-Benefit Analysis
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Quality of Life
Treatment Outcome
Humans
United States

41. Inotersen and patisiran for hereditary transthyretin amyloidosis: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
Subject(s):
Amyloidosis, Familial -- drug therapy
RNA, Small Interfering -- therapeutic use
Amyloid Neuropathies, Familial -- drug therapy
Amyloidosis, Familial -- complications
Clinical Trials as Topic
Cost-Benefit Analysis
RNA, Small Interfering -- adverse effects
RNA, Small Interfering -- economics
Treatment Outcome
Humans
United States

42. Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018
Subject(s):
Androgen Antagonists -- therapeutic use
Prostatic Neoplasms -- drug therapy
Androgen Antagonists -- adverse effects
Cost-Benefit Analysis
Disease Progression
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

43. Prophylaxis for hereditary angioedema with lanadelumab and C1 Inhibitors: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, November 25, 2018
Subject(s):
Angioedemas, Hereditary -- drug therapy
Angioedemas, Hereditary -- prevention & control
Antibodies, Monoclonal, Humanized -- therapeutic use
Complement C1 Inhibitor Protein -- therapeutic use
Kallikreins -- antagonists & inhibitors
Antibodies, Monoclonal, Humanized -- adverse effects
Antibodies, Monoclonal, Humanized -- economics
Complement C1 Inhibitor Protein -- adverse effects
Complement C1 Inhibitor Protein -- economics
Cost-Benefit Analysis
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

44. Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 3, 2018
Subject(s):
Analgesics, Opioid -- therapeutic use
Narcotic Antagonists -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Buprenorphine, Naloxone Drug Combination -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Treatment Outcome
Humans
United States

45. Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2018
Subject(s):
Antibodies, Monoclonal -- therapeutic use
Asthma -- drug therapy
Inflammation -- drug therapy
Antibodies, Monoclonal -- adverse effects
Antibodies, Monoclonal -- economics
Biological Therapy
Cost-Benefit Analysis
Hypersensitivity -- drug therapy
Inflammation -- complications
Treatment Outcome
Humans
United States

46. Cost containment in Medicare: a review of what works and what doesn't

Publication:
Washington, D.C. : AARP Public Policy Institute, c2008
Subject(s):
Cost Control -- methods
Medicare -- economics
Chronic Disease
Cost-Benefit Analysis
Cost Sharing
Disease Management
Fee Schedules
Fraud -- prevention & control
Home Care Services -- economics
Insurance Coverage
Nursing Homes -- economics
Prospective Payment System -- economics
Humans
United States

47. Challenges to sustaining California's developmental disability services system

Publication:
Los Angeles, Calif. : UCLA Center for Health Policy Research, March 2011
Subject(s):
Community Health Services -- economics
Developmental Disabilities -- prevention & control
Health Care Rationing -- trends
Age Factors
Budgets
Cost-Benefit Analysis
Developmental Disabilities -- epidemiology
Efficiency, Organizational
Eligibility Determination
Forecasting
Health Care Costs -- trends
Health Expenditures
Health Services Accessibility
Quality of Health Care
Rate Setting and Review
State Government
Humans
United States

48. California's nurse practitioners: how scope of practice laws impact care

Author(s):
Spetz, Joanne, author
Publication:
[Oakland, Calif.] : California Health Care Foundation, September 2018
Subject(s):
Health Workforce -- statistics & numerical data
Nurse Practitioners -- statistics & numerical data
Nurse's Role
Quality of Health Care
Cost-Benefit Analysis
Government Regulation
Health Services Accessibility
Nurse Practitioners -- education
Primary Health Care
State Government
Humans
California
United States

49. What difference does Medicaid make?: assessing cost effectiveness, access, and financial protection under Medicaid for low-income adults

Author(s):
Coughlin, Teresa A., author
Long, Sharon K., author
Clemans-Cope, Lisa, author
Resnick, Dean, author
Publication:
Menlo Park, CA : Kaiser Commission on Medicaid and the Uninsured, 2013
Subject(s):
Cost-Benefit Analysis
Health Services Accessibility -- economics
Health Services -- statistics & numerical data
Insurance Coverage -- legislation & jurisprudence
Insurance, Health -- economics
Medicaid -- legislation & jurisprudence
United States
United States.

55. VA health care facilities: leveraging partnerships to address capital investment needs : testimony before the Subcommittee on Health, Committee on Veterans’ Affairs, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, May 12, 2022
Subject(s):
Cost-Benefit Analysis
Government Regulation
Hospitals, Veterans
Public-Private Sector Partnerships -- organization & administration
United States
United States. Department of Veterans Affairs

56. Saving lives and reducing health care costs: how Clean Air Act rules benefit the nation : a report from Trust for America's Health, EDF Environmental Defense Fund

Publication:
[Washington, D.C.] : Trust for America's Health, November 2011
Subject(s):
Air Pollution -- legislation & jurisprudence
Cost Savings
Environmental Illness -- prevention & control
Health Promotion
Air Pollutants -- adverse effects
Air Pollution -- prevention & control
Air Pollution -- statistics & numerical data
Cost-Benefit Analysis
Environmental Illness -- epidemiology
Financing, Government -- statistics & numerical data
Financing, Personal -- statistics & numerical data
Health Care Costs
Insurance, Health -- economics
Medicaid
Medicare
Mortality
Humans
United States
United States.
United States. Environmental Protection Agency.

57. Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications: guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, August 30, 2019
Subject(s):
Cost-Benefit Analysis
Device Approval
Equipment and Supplies -- classification
Equipment Safety -- classification
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

58. Consideration of uncertainty in making benefit-risk determinations in medical device premarket approvals, de novo classifications, and humanitarian device exemptions: guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, August 30, 2019
Subject(s):
Compassionate Use Trials -- standards
Cost-Benefit Analysis
Device Approval -- standards
Equipment and Supplies -- classification
Uncertainty
Data Collection
Reagent Kits, Diagnostic
Research Design
Sample Size
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

60. Examining the cost effectiveness of teaching health centers

Author(s):
Chen, Candice, author
Ku, Leighton, author
Regenstein, Marsha, author
Mullan, Fitzhugh, author
Publication:
[Washington, D.C.] : Milken Institute School of Public Health, George Washington University, March 2019
Subject(s):
Education, Medical, Graduate -- economics
Hospitals, Teaching -- economics
Medically Underserved Area
Community Health Centers
Cost Savings
Cost-Benefit Analysis
Education, Medical -- economics
Government Programs -- economics
Medicaid -- economics
Medicare -- economics
Physicians, Primary Care
Primary Health Care -- economics
Humans
United States

Refine by:

more »

more »

more »

Current results range from 1976 to 2022